Vocabria

Generic Name: cabotegravir

Drug Class: Integrase Inhibitors

Company: ViiV Healthcare

Approval Status: Approved

Generic Version Available: No

Drug Indication

Cabotegravir is a medication for HIV treatment. Vocabria pills are approved for use with Edurant (rilpivirine) as a short-term treatment regimen. Vocabria has not yet been reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.

Visit https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/ for the full DHHS guidelines for adults and adolescents.

Cabenuva is a long-acting treatment regimen that consists of extended-release cabotegravir and rilpivirine injections. Long-acting injectable cabotegravir is also approved for pre-exposure prophylaxis (PrEP) as Apretude.

General Info

Vocabria is an integrase inhibitor antiretroviral medication. It is used with Edurant (rilpivirine) for short-term HIV treatment. The pills are used as a lead-in regimen for people who want to switch to Cabenuva injections and may be substitute if someone has to miss a planned injection appointment.

Dosage

Dosing Info:

Vocabria pills are taken once daily, in combination with once-daily Edurant pills, as a oral lead-

in regimen for a month before switching to Cabenuva injections.

Side Effects

The most commonly reported side effects are headache, nausea, abnormal dreams, anxiety and insomnia.

Drug Interactions

For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Vocabria or may require dose adjustments, consult the Vocabria package insert.

Other Info

https://www.poz.com/article/viiv-applies-approval-first-longacting-injectable-hiv-regimen

---

For More Info: https://viivhealthcare.com/en-gb/our-medicines/vocabria/

Patient Assistance Program Info: https://www.viivconnect.com/patient-assistance-program/

Last Reviewed: August 5, 2025

© 2026 Smart + Strong All Rights Reserved.